Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...

HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Chinese scientists are celebrating a new breakthrough cancer drug, but some Chinese citizens are skeptical of domestically ...

Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...

Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III clinical trials. Over 2,300 patients have been treated with ivonescimab in clinical ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.